Logo for Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Investor Relations Material

Latest events

Logo for Vanda Pharmaceuticals Inc

Q4 2023

Vanda Pharmaceuticals
Logo for Vanda Pharmaceuticals

Q4 2023

7 Feb, 2024
Logo for Vanda Pharmaceuticals

Q3 2023

8 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Vanda Pharmaceuticals Inc

Access all reports
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ (tasimelteon) for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone) for the treatment of bipolar disorder. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder and smith-magenis syndrome; Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness; Fanapt oral tablets for the treatment of schizophrenia; Novel fixed dose combination products: anoro progesterone vaginal system/norethindrone acetate tablets in women